Literature DB >> 12727359

Endotoxic and immunobiological activities of a chemically synthesized lipid A of Helicobacter pylori strain 206-1.

Tomohiko Ogawa1, Yasuyuki Asai, Yasuhiro Sakai, Masato Oikawa, Koichi Fukase, Yasuo Suda, Shoichi Kusumoto, Toshihide Tamura.   

Abstract

A synthetic lipid A of Helicobacter pylori strain 206-1 (compound HP206-1), which is similar to its natural lipid A, exhibited no or very low endotoxic activities as compared to Escherichia coli-type synthetic lipid A (compound 506). Furthermore, compound HP206-1 as well as its natural lipid A demonstrated no or very low mitogenic responses in murine spleen cell. On the other hand, compound HP206-1 showed a weaker but significant production of interleukin-8 in a gastric cancer cell line, MKN-1, in comparison with compound 506. Furthermore, compound HP206-1 exhibited induction of tumor necrosis factor-alpha production in human peripheral blood mononuclear cells and the cytokine production was clearly inhibited by mouse anti-human Toll-like receptor (TLR) 4 monoclonal antibody HTA125. Our findings indicate that the chemically synthesized lipid A, mimicking the natural lipid A portion of lipopolysaccharide from H. pylori strain 206-1, has a low endotoxic potency and immunobiological activities, and is recognized by TLR4.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12727359     DOI: 10.1016/S0928-8244(03)00093-2

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  23 in total

1.  Free lipid A isolated from Porphyromonas gingivalis lipopolysaccharide is contaminated with phosphorylated dihydroceramide lipids: recovery in diseased dental samples.

Authors:  Frank C Nichols; Bekim Bajrami; Robert B Clark; William Housley; Xudong Yao
Journal:  Infect Immun       Date:  2011-12-05       Impact factor: 3.441

Review 2.  Progress in the synthesis and biological evaluation of lipid A and its derivatives.

Authors:  Jian Gao; Zhongwu Guo
Journal:  Med Res Rev       Date:  2017-06-16       Impact factor: 12.944

3.  Implication of antigenic conversion of Helicobacter pylori lipopolysaccharides that involve interaction with surfactant protein D.

Authors:  Shin-ichi Yokota; Ken-ichi Amano; Chiaki Nishitani; Shigeru Ariki; Yoshio Kuroki; Nobuhiro Fujii
Journal:  Infect Immun       Date:  2012-05-21       Impact factor: 3.441

4.  A novel 3-deoxy-D-manno-octulosonic acid (Kdo) hydrolase that removes the outer Kdo sugar of Helicobacter pylori lipopolysaccharide.

Authors:  Christopher Stead; An Tran; Donald Ferguson; Sara McGrath; Robert Cotter; Stephen Trent
Journal:  J Bacteriol       Date:  2005-05       Impact factor: 3.490

Review 5.  Colonize, evade, flourish: how glyco-conjugates promote virulence of Helicobacter pylori.

Authors:  Erica J Rubin; M Stephen Trent
Journal:  Gut Microbes       Date:  2013-07-12

6.  Periplasmic cleavage and modification of the 1-phosphate group of Helicobacter pylori lipid A.

Authors:  An X Tran; Mark J Karbarz; Xiaoyuan Wang; Christian R H Raetz; Sara C McGrath; Robert J Cotter; M Stephen Trent
Journal:  J Biol Chem       Date:  2004-10-15       Impact factor: 5.157

7.  Lactobacilli inhibit interleukin-8 production induced by Helicobacter pylori lipopolysaccharide-activated Toll-like receptor 4.

Authors:  Chao Zhou; Feng-Zhen Ma; Xue-Jie Deng; Hong Yuan; Hong-Sheng Ma
Journal:  World J Gastroenterol       Date:  2008-08-28       Impact factor: 5.742

8.  Helicobacter pylori lipopolysaccharide: biological activities in vitro and in vivo, pathological correlation to human chronic gastritis and peptic ulcer.

Authors:  Yi-Hui Luo; Jie Yan; Ya-Fei Mao
Journal:  World J Gastroenterol       Date:  2004-07-15       Impact factor: 5.742

9.  Lactic acid bacterial extracts as anti-Helicobacter pylori: a molecular approach.

Authors:  H El-Adawi; M El-Sheekh; M Khalil; N El-Deeb; M Hussein
Journal:  Ir J Med Sci       Date:  2013-02-13       Impact factor: 1.568

10.  Helicobacter pylori lipopolysaccharides upregulate toll-like receptor 4 expression and proliferation of gastric epithelial cells via the MEK1/2-ERK1/2 mitogen-activated protein kinase pathway.

Authors:  Shin-Ichi Yokota; Tamaki Okabayashi; Michael Rehli; Nobuhiro Fujii; Ken-Ichi Amano
Journal:  Infect Immun       Date:  2009-10-26       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.